No products in the cart.
Pre-made Anetumab benchmark antibody ( Whole mAb ADC, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-025
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Anetumab biosimilar, Whole mAb ADC, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Anetumab ravtansine, here referred to as BAY 94-9343, a novel ADC consisting of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4 via a disulfide-containing linker.
| Products Name (INN Index) | Pre-Made Anetumab biosimilar, Whole mAb ADC, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody |
|---|---|
| INN Name | Anetumab |
| Target | MSLN |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Bayer HealthCare,ImmunoGen,MorphoSys,National Cancer Institute (USA) |
| Conditions Approved | NA |
| Conditions Active | Lung cancer,Mesothelioma,Ovarian cancer,Pancreatic cancer,Solid tumours,Non-small cell lung cancer,Malignant thymoma |
| Conditions Discontinued | Fallopian tube cancer,Peritoneal cancer |
| Development Tech | MorphoSys HuCAL Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | MSLN |
| Package |
Previous slide
Next slide
